Highlights

Solutions

Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.

Highlights

Platforms

To accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.

Highlights

Anti-PSCA CAR-T Preclinical in vivo Assay

Our collaborative approach and deep scientific and regulatory understanding of various drug discovery and development solutions helps us shape the best strategy for bringing a novel therapy to market and design custom studies and programs that reduce risk and accelerate timelines.

CONTACT US

Anti-PSCA CAR-T Preclinical in vivo Assay

Target Background

PSCA (prostate stem cell antigen) or PSA (prostate-specific antigen), also known as gamma-seminoprotein or kallikrein-3 (KLK3), encodes a glycosylphosphatidylinositol-anchored cell membrane glycoprotein belonging to the kallikrein-related peptidase family, which is almost exclusively expressed and secreted by the epithelial cells in the prostate for its namesake, as well as in the bladder, placenta, colon, kidney and stomach. Physiologically, PSCA functions as a serine protease to liquefy semen in the seminal coagulum and dissolve cervical mucus to liberate sperm and allow entry into the uterus. Pathologically, PSCA is up-regulated in a large proportion of prostate, bladder and pancreas cancers, especially of primary and metastatic prostate cancers. In the United States, the U. S. Food and Drug Administration (FDA) has approved the PSCA test for annual screening of prostate cancer in men of age 50 and older. On account of the unparalleled role in promoting the growth and metastasis of prostate cancer, and the extremely restricted expression in the prostate, PSCA is manifested as an important diagnostic marker and a promising therapeutic target for a safer and more effective immunotherapy.

Structure of PSA complex with a substrat-acyl intermediate and an activating antibody
Diagram created by Creative Biolabs based on data from Journal of molecular biology 376.4 (2008): 1021-1033

Anti-PSCA CAR-T Cell Therapy

Since T cells genetically engineered with a chimeric antigen receptor (CAR) has been successfully applied on several human malignancies, two phase 1 clinical trials (NCT02744287 and NCT01140373) have been designed to test the feasibility and safety of anti-PSCA chimeric antigen receptor engineered T cells in subjects with non-resectable pancreatic cancer and castrate metastatic prostate cancer respectively. Creative Biolabs will help researchers create and perform the most cutting-edge anti-PSCA CAR-T cell therapy in the world.

Animal Models for in vivo Study of anti-PSCA CAR-T Cell Therapy

Creative Biolabs endows researchers with versatile laboratory and clinical animal models of all human malignancies. Below is an example of transgenic mouse models of prostate cancer.

Creative Biolabs outperforms the entire biotechnological community to back researchers with every resource for establishing the most reliable and subtle animal models in advance to help the customer achieve incredible disproportionate results and exponentially greater value. Creative Biolabs assists researchers in making the scientific history.

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.